Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.

Abstract

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

• Authors: Aurelio Maggio, Angela Vitrano, Gaetano Lucania, Marcello Capra, Liana Cuccia, Francesco Gagliardotto, Lorella Pitrolo, Luciano Prossomariti, Aldo Filosa, Vincenzo Caruso, Calogera Gerardi, Saveria Campisi, Paolo Cianciulli, Michele Rizzo, Giuseppe D'Ascola, Angela Ciancio, Rosario Di Maggio, Giuseppina Calvaruso, Gaetano Restivo Pantalone, Paolo Rigano
• Journal: American journal of hematology (Am J Hematol) Vol. 87 Issue 7 Pg. 732-3 (Jul 2012) ISSN: 1096-8652 [Electronic] United States
• PMID: 22622672 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Iron Chelating Agents
• Pyridones
• Deferiprone
• Deferoxamine

Topics

• Adult
• Deferiprone
• Deferoxamine (administration & dosage, therapeutic use)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Heart Ventricles (diagnostic imaging, drug effects, physiopathology)
• Humans
• Iron Chelating Agents (administration & dosage, adverse effects)
• Male
• Models, Biological
• Pyridones (administration & dosage, therapeutic use)
• Retrospective Studies
• Stroke Volume (drug effects)
• Time Factors
• Ultrasonography
• beta-Thalassemia (drug therapy, physiopathology)